



On 30th Anniversary of Initial AIDS Diagnoses bioLytical Laboratories Lauds Progress to Date; says its INSTI™ Rapid HIV Test Can Make Even Greater Difference

June 6th 2011

Surrey, CANADA – Thirty years after the first reported cases of AIDS in the United States, the research and development carried out by Canadian life sciences firm bioLytical Laboratories represents an important contribution to addressing the HIV/AIDS epidemic.

The alarming speed with which AIDS spread to and claimed countless lives when it was first identified in 1981, proved devastating for the international community – not least because of its struggle to find a solution. Over the past three decades, however, a remarkable amount of research has resulted in significant gains in the prevention and treatment of HIV/AIDS. Thanks to a global commitment to eradicate this devastating disease, millions of lives have been saved while millions more have been transformed.

As the developer of the INSTI™ HIV Antibody Test, the world's only 60-second antibody detection test, recognized as the fastest diagnostic HIV test in the world, bioLytical Laboratories has contributed both to the diagnosis of HIV positive patients, and the process of preventing the spread of infection to others.

The company has played a key role in improving accessibility and efficiency of HIV testing across Canada and in other countries around the world, ultimately making the treatment and prevention of HIV/AIDS a more attainable, and cost-effective goal for patients and their health care providers, particularly in hard-to-reach, and high-risk communities.

“The 30th anniversary is a significant milestone in HIV/AIDS awareness and research, and it's important to recognize how far we've come in terms of treatment, education, and prevention since AIDS was first diagnosed,” says Rick Galli, Chief Technical Officer of bioLytical Laboratories. “However, there is a long way to go. INSTI™ can extend the reach and productivity of existing testing programs and thus enhance HIV detection and prevention.”

To date, bioLytical's revolutionary INSTI™ rapid HIV Antibody test is the only point-of-care rapid HIV Antibody test approved by Health Canada. It continues to transform the face of HIV/AIDS awareness across the globe, and remains an important tool in international efforts to eradicate the disease, especially in light of the encouraging results of the HPTN 052 clinical trial, which suggests that early diagnosis and treatment of HIV patients significantly reduces their likelihood of transmitting the virus.

For more information, call bioLytical™ at 888-316-0351 or visit www.biolytical.com.

-30-

Media Contact

Rebecca Peters
Laura Ballance Media Group
604.637.6649 (direct)
604.762.2098 (mobile)
Rebecca@LBMG.ca